In this episode, Lindsey Greenleaf, JD, MBA, leader in federal and state policy at ADVI Health and Pam Traxel, senior VP of alliance development and philanthropy at American Cancer Society, Cancer Action Network, discuss the impact of policy updates.
Find the CANCER BUZZ podcast on Apple Podcasts, Spotify, or wherever you get your podcasts!
It is crucial that multidisciplinary cancer care teams stay informed about upcoming changes to Medicare Part D under the Inflation Reduction Act. To support this effort, the Association of Cancer Care Centers (ACCC) is committed to providing updated information on health care policy changes, ensuring that both providers and patients are aware of the financial benefits. In this episode, CANCER BUZZ speaks with Lindsey Greenleaf, JD, MBA, solution leader in federal and state policy at ADVI Health and Pam Traxel, senior vice president of alliance development and philanthropy at American Cancer Society, Cancer Action Network, to discuss the impact of these policy updates. Ms. Greenleaf sheds light on the $2,000 out-of-pocket cap that will take place for Part D patients in 2025 and how future pricing policy could have an effect on drug innovation. Ms. Traxel expands on benefits and challenges involved with providing updates to oncologists on the new Medicare Part D cap, with the goal of ensuring that all patients who could benefit are aware. “I think the most important thing that oncologists and their practices can do is to make sure that they are providing information to patients about the fact that there is a change that will hopefully allow patients to better afford their cancer care.” -Pam Traxel “The second key piece of the Inflation Reduction Act related to Part D has to do with Part D benefit redesign, and that is what kicks in January 1, 2025, and that is a very notable, very positive change to the law where we finally have a $2,000 out-of-pocket cap that will be in place for Part D patients. This is a huge win for cancer patients, specifically due to the historically very high out-of-pocket costs for oral cancer drugs.” -Lindsey Greenleaf
Guest:
Lindsay Greenleaf, JD, MBA
Solution Leader, Federal & State Policy
ADVI Health, LLC
Austin, TX
Pam Traxel
Senior Vice President of Alliance Development and Philanthropy
American Cancer Society, Cancer Action Network
Silver Spring, MD
This podcast was developed in connection with the Oncology State Society Policy Program and made possible with support by Johnson & Johnson.
Additional Resources:
The views and opinions expressed herein are those of the author(s)/faculty member(s) and do not reflect the official policy or position of their employer(s) or the Association of Cancer Care Centers.
September 10, 2026
